Skip to content

Evaluation of the PrevisEA Device for Predicting Gastrointestinal Impairment

A Minimal-Risk, Multi-Center, Prospective, Clinical Trial to Evaluate the PrevisEA Device for Predicting Gastrointestinal Impairment

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04880473
Enrollment
400
Registered
2021-05-10
Start date
2021-09-14
Completion date
2024-12-01
Last updated
2024-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Complication

Keywords

Postoperative ileus, Postoperative bowel obstruction, Emesis, Reversal of diet, Nasogastric tube, Abdominal sounds, Gastrointestinal impairment, Elective intestinal resection

Brief summary

PrevisEA is a noninvasive, disposable device that uses audio spectral analysis of sounds produced by the gastrointestinal tract to predict gastrointestinal impairment (GII). GII is most commonly associated with postoperative ileus (POI), but could be the result of other causes, such as early postoperative bowel obstruction. GII is defined as failure of successful early oral re-feeding in a subject undergoing major abdominal surgery. For subjects who are allowed to resume a diet during the first 24 hours after surgery, a failure to successfully orally re-feed a subject is defined as presentation with emesis, requiring a reversal of diet, or the placement of a nasogastric tube on first postoperative day or later. The device is considered non-significant risk (NSR). The device does not inform medical decisions in this study. Researchers will be blinded to results of the device during this study.

Interventions

DEVICEPrevisEA device

The PrevisEA device is placed and activated on the patient's abdomen immediately post-op (within 1 hour of the completion of surgery) and maintained in position for at least 12 hours, counting the number of times MH4 is detected within a four-minute period at hourly intervals. The device determines the MH4 biomarker counts at each hourly collection point and the data are stored on the device. Under normal conditions, transformations of the data are visualized on the display. For this clinical trial, the display is obscured. Therefore, no value will be displayed for interpretation since this is a non-intervention trial and the device is not intended to affect or influence the standard of care for study participants.

Sponsors

Entac Medical Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

1. Age ≥ 18 and ≤ 90 years 2. Patient undergoing elective intestinal resection surgery including open, laparoscopic, robotic, or hand-assist technique for: 1. Segmental ileocolic resection with or without diversion 2. Segmental colon resection with or without diversion 3. Segmental coloproctectomy with or without diversion 4. Low anterior resection with or without diversion 5. Abdominoperineal resection 6. Total abdominal colectomy with or without diversion 7. Proctocolectomy with or without end ileostomy or diversion 8. Closure of end colostomy (Hartmann's reversal)

Exclusion criteria

1. Allergies to any of the device components (i.e., adhesive) 2. Inability to have prototype device applied to their abdominal wall due to disease conditions or surgical alterations(e.g., fistulas, stomas, drains, etc.) 3. Patients undergoing: 1. Small bowel resection without colonic resection 2. Transanal proctectomy without transabdominal approach 3. Perineal proctosigmoidectomy 4. Closure of loop colostomy or ileostomy 4. Patients with preoperative evidence of an anastomotic leak, deep wound infection, organ space infection, or urinary tract infection

Design outcomes

Primary

MeasureTime frameDescription
Performance of the PrevisEA device1-14 daysThe performance (accuracy) of the device in predicting development of GII will be assessed through evaluation of the primary outcome measures of sensitivity and specificity for the device.

Secondary

MeasureTime frameDescription
Positive predictive value (PPV)1-14 daysMeasures will be analyzed by using available data only
Negative predictive value (NPV)1-14 daysMeasures will be analyzed by using available data only
Overall percent agreement (OPA)1-14 daysMeasures will be analyzed by using available data only

Countries

United States

Contacts

Primary ContactEntac Medical Inc.
previsea-001@clinicalresearchstrategies.com845-773-8473

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026